Skip to main content


Fig. 1 | Experimental Hematology & Oncology

Fig. 1

From: Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide

Fig. 1

Ibrutinib interferes with immune mediated cell death induced by anti-CD20 antibody in MCL cell lines. Cell death (%) ± standard deviation in MCL cell lines (JeKo -1, REC-1), opsonized with 1 μM anti-CD20 mAb (rituximab, obinutuzumab) and co-cultured with PBMC pretreated with ibrutinib (0-5 µM). Results were compared by unpaired student’s t-test. * = p<0.05. R rituximab, O obinutuzumab

Back to article page